Official Title
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.


Drug: LY2503029
Administered orally.

Drug: LY3023414
Administered orally.

Eligibility Criteria

Inclusion Criteria: - To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria: - Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Eligibility Gender
Eligibility Age
Minimum: 18 Years
United States

UCLA Medical Center
Torrance, California, 90505


Contact: 310-325-8252

Investigator: Dr. Parvin Fatheddin Peddi

Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, 46804


Contact: 260-436-0800

Investigator: Dr. Sunil Babu

Sarah Cannon Cancer Center
Nashville, Tennessee, 37203


Contact: 615-329-7274

Investigator: Dr. Howard A. Burris III


There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
Study Director
Eli Lilly and Company

Eli Lilly and Company
NCT Number